WO2013018069A1 - Combinaison d'agents antipaludéens - Google Patents

Combinaison d'agents antipaludéens Download PDF

Info

Publication number
WO2013018069A1
WO2013018069A1 PCT/IB2012/053984 IB2012053984W WO2013018069A1 WO 2013018069 A1 WO2013018069 A1 WO 2013018069A1 IB 2012053984 W IB2012053984 W IB 2012053984W WO 2013018069 A1 WO2013018069 A1 WO 2013018069A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzyl
piperazin
ethyl
oxo
acetyl
Prior art date
Application number
PCT/IB2012/053984
Other languages
English (en)
Inventor
Christoph Boss
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of WO2013018069A1 publication Critical patent/WO2013018069A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a combination comprising a compound of the formula I and one or more other antimalarial agent, especially for use as a medicament to treat or prevent malaria infections or to treat or prevent other protozoal diseases like sleeping sickness, Chagas disease, amebiasis, giardiasis, trichomoniasis, toxoplasmosis, and leishmaniasis.
  • a compound of the formula I especially for use as a medicament to treat or prevent malaria infections or to treat or prevent other protozoal diseases like sleeping sickness, Chagas disease, amebiasis, giardiasis, trichomoniasis, toxoplasmosis, and leishmaniasis.
  • Malaria is one of the most serious and complex health problems affecting civilization in the 21 st century. The disease affects about 300 million people worldwide, killing 1 to 1.5 million people every year. Malaria is an infectious disease caused by four species of the protozoan parasite Plasmodium, P. falciparum being the most severe of the four. All attempts to develop vaccines against P. falciparum have failed so far. Therefore, therapies and preventive measures against malaria are confined to drugs.
  • P. falciparum enters the human body by way of bites of the female anophelino mosquito (it may also be transmitted by blood transfusion from asymptotic donors; almost all infected blood components including red cells, platelet concentrates, white cells, cryoprecipitates and fresh plasma can transmit malaria).
  • the Plasmodium parasite initially populates the liver, and during later stages of the infectious cycle reproduces in red blood cells. During this stage, the parasite degrades hemoglobin and uses the degradation products as nutrients for growth.
  • the present invention relates to low molecular weight, non-peptidic, non-quinoline compounds of formula I in combination with one or more other antimalarial agent which combinations are useful in the treatment and/or prevention of protozoal infections, especially in the treatment and/or prevention of malaria, in particular Plasmodium falciparum malaria.
  • the present invention relates to a combination comprising a compound of the formula I:
  • ⁇ X is CH or N
  • R represents -N0 2 , -N(CH 3 ) 2 , or -NCH 3 (CH 2 CH 2 OH);
  • R 2 represents hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl, cyano, halogen, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, difluoromethoxy, methylsulfonyl, acetyl, or acetylamino; or
  • ⁇ X is CH, R is hydrogen, and R 2 is ethyl, isopropyl, tert-butyl, ethoxy, n-propoxy, isopropoxy, methylsulfonyl, acetylamino, or methoxycarbonyl; or
  • ⁇ X is CH, R is cyano, and R 2 is ethyl, isopropyl, tert-butyl, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, methylsulfonyl, or acetylamino; or
  • ⁇ X is CH, R is chloro, and R 2 is ethyl, isopropyl, tert-butyl, ethoxy, n-propoxy, isopropoxy, difluoromethoxy, methylsulfonyl, or acetylamino; or
  • ⁇ X is CH, R is methoxy or isopropoxy, and R 2 is trifluoromethyl; or
  • ⁇ X is CH, R is methylsulfonyl or ethylsulfonyl, and R 2 is trifluoromethyl, ethyl, isopropyl, tert-butyl, ethoxy, n-propoxy, isopropoxy, or difluoromethoxy, such as especially trifluoromethyl, tert-butyl, n-propoxy, or isopropoxy;
  • a further embodiment of the invention relates to the combination according to embodiment i), wherein in addition to a compound of formula I, the combination contains only one other antimalarial agent.
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is selected from the group consisting of:
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is selected from the group consisting of:
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is selected from the group consisting of:
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is selected from the group consisting of:
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is selected from the group consisting of:
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is (S)-N-[4-(4-acetyl-piperazin-1 -yl)- benzyl]-N-[1 -benzyl-2-(4-benzyl-piperazin-1 -yl)-2-oxo-ethyl]-3-(4-tert-butyl-phenyl)- acrylamide or a salt thereof.
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is (S)-N-[4-(4-acetyl-piperazin-1 -yl)- benzyl]-N-[1 -benzyl-2-(4-benzyl-piperazin-1 -yl)-2-oxo-ethyl]-3-(4-propoxy-phenyl)- acrylamide or a salt thereof.
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is (S)-N-[4-(4-acetyl-piperazin-1 -yl)- benzyl]-N- ⁇ 1 -benzyl-2-[4-(4-cyano-benzyl)-piperazin-1 -yl]-2-oxo-ethyl ⁇ -3-(4-ethoxy-phenyl)- acrylamide or a salt thereof.
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is (S)-N-[4-(4-acetyl-piperazin-1 -yl)- benzyl]-N- ⁇ 1 -benzyl-2-[4-(4-cyano-benzyl)-piperazin-1 -yl]-2-oxo-ethyl ⁇ -3-(4-tert-butyl- phenyl)-acrylamide or a salt thereof.
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is (S)-N-[4-(4-acetyl-piperazin-1 -yl)- benzyl]-N-[1 -benzyl-2-(4- ⁇ 4-[(2-hydroxy-ethyl)-methyl-amino]-benzyl ⁇ -piperazin-1 -yl)-2-oxo- ethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide or a salt thereof.
  • a further embodiment of the invention relates to the combination according to embodiment i) or ii), wherein the compound of formula I is (S)-N-[4-(4-acetyl-piperazin-1 -yl)- benzyl]-N-[1 -benzyl-2-(4- ⁇ 4-[(2-hydroxy-ethyl)-methyl-amino]-benzyl ⁇ -piperazin-1 -yl)-2-oxo- ethyl]-3-(4-isopropoxy-phenyl)-acrylamide or a salt thereof.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of Quinine and other related antimalarials (interfering with heme-polymerization / parasite detoxification pathways) from the 4-aminoquinoline- and the arylaminoalcohol class such as Quinidine, Chloroquine, Amodiaquine, Mefloquine, Halofantrine, Lumefantrine (Benflumetol), Desbutyllumefantrine, Pyronaridine, Piperaquine, Mepacrine, Sontoquine, AQ13, F2Bu, Tebuquine, Isoquine, FAQ4, and Naphthoquine.
  • Quinine and other related antimalarials interfering with heme-polymerization / parasite detoxification pathways
  • the 4-aminoquinoline- and the arylaminoalcohol class such as Quinidine
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of antifolate-agents, for example dihydrofolate reductase inhibitors such as Pyrimethamine, Proguanil / Cycloguanil, Chloroproguanil / Chlorocycloguanil, and PS-15 / Cyclo-PS-15.
  • antifolate-agents for example dihydrofolate reductase inhibitors such as Pyrimethamine, Proguanil / Cycloguanil, Chloroproguanil / Chlorocycloguanil, and PS-15 / Cyclo-PS-15.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of dihydropteroate-synthase inhibitors such as sulfadoxine and dapsone.
  • the other antimalarial agent is selected from the group consisting of trimethoprime, WR99210, and JPC-2056.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of Artemisinine and derivatives thereof, such as Artemisinine, Dihydroartemisinine, Artemether, Arteether, Artesunate, Artelinate, Artemisone, Artelinic acid and further compounds as described in J. Wiesner et al., Angewandte Chemie, 2003, 115, 5432-5451 , specifically pages 5443-5444, chapter 5.2).
  • the other antimalarial agent is selected from the group consisting of Artemisinine and derivatives thereof, such as Artemisinine, Dihydroartemisinine, Artemether, Arteether, Artesunate, Artelinate, Artemisone, Artelinic acid and further compounds as described in J. Wiesner et al., Angewandte Chemie, 2003, 115, 5432-5451 , specifically pages
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of RKA 182 and related compounds (J. Chadwick et al. ChemMedChem, 2011 ; DOI: 10.1002/cmdc.201 100196).
  • the other antimalarial agent is selected from the group consisting of antibiotics active against malaria parasites such as Rifampicine, Doxycycline, Clindamycin, and Azithromycin.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of inhibitors of mitochondrial electrone transfer such as Atovaquone, Lapinone, Menoctone, Pravaquone, BW58C80, and Buparvaquone.
  • the other antimalarial agent is selected from the group consisting of 8-aminoquinoline based compounds such as Pamaquine, Tafenoquine, Primaquine, Quinocide, NCP1 161 B, and Bulaquine.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of inhibitors of the mevalonate independent isoprenoide biosynthesis such as Fosmidomycine, FR900098 and produgs of FR900098.
  • the other antimalarial agent is selected from the group consisting of inhibitors of the mevalonate independent isoprenoide biosynthesis such as Fosmidomycine, FR900098 and produgs of FR900098.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of antimalarials interfering with heme-polymerization / parasite detoxification pathways such as WR-243251 , Floxacrine, 2,7-Dibromocryptolepine, Ro 06-9075, and Ro 22-8014.
  • the other antimalarial agent is selected from the group consisting of antimalarials interfering with heme-polymerization / parasite detoxification pathways such as WR-243251 , Floxacrine, 2,7-Dibromocryptolepine, Ro 06-9075, and Ro 22-8014.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of endoperoxides such as Yingzhaosu A, Arteflen, OZ277 / Arterolane and related synthetic trioxolane based compounds, and OZ439 and related synthetic trioxolane based compounds.
  • the other antimalarial agent is selected from the group consisting of trioxaquines such as DU-1 102.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of protease inhibitors (e.g. falcipain inhibitors or plasmepsin inhibitors), inhibitors of fatty acid synthesis (e.g. triclosan and analogues), inhibitors of choline uptake (e.g. ammonium salts such as E10 or bis-ammonium salts such as G25 or MS1 ), farnesyl- transferase inhibitors (e.g. FTI-2153 and Schl-41 16), glycolysis inhibitors (e.g.
  • protease inhibitors e.g. falcipain inhibitors or plasmepsin inhibitors
  • inhibitors of fatty acid synthesis e.g. triclosan and analogues
  • inhibitors of choline uptake e.g. ammonium salts such as E10 or bis-ammonium salts such
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is ferroquine.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xiii), wherein the other antimalarial agent is selected from the group consisting of Quinidine, Chloroquine, Amodiaquine, Mefloquine, Halofantrine, Lumefantrine (Benflumetol), Desbutyllumefantrine, Pyronaridine, Piperaquine, Mepacrine, Sontoquine, AQ13, F2Bu, Tebuquine, Isoquine, FAQ4, Naphthoquine, Pyrimethamine, Proguanil / Cycloguanil, Chloroproguanil / Chlorocycloguanil, PS-15 / Cyclo-PS-15, sulfadoxine, dapsone, trimethoprime, WR99210, JPC-2056, Artemisinine, Dihydroartemisinine, Artemether, Arteether, Artesunate, Artelinate,
  • a further embodiment of the invention relates to a combination according to embodiment i) comprising a compound of formula I as defined in any one of embodiments i) to xiii), or a salt thereof, and two or more (preferably two or three and most preferably two) other antimalarial agents independently selected from the antimalarial agents listed in any one of embodiments xiv) to xxix).
  • xxxi) A further embodiment of the invention relates to the combination according to any one of embodiments i) to xxx), for use as a medicament.
  • xxxii) A further embodiment of the invention relates to the combination according to any one of embodiments i) to xxx), for use in the treatment and/or prevention of protozoal infections.
  • a further embodiment of the invention relates to the combination according to any one of embodiments i) to xxx), for use in the treatment and/or prevention of malaria.
  • xxxiv) A further embodiment of the invention relates to the combination according to any one of embodiments i) to xxx) for use according to any one of embodiments xxxi) to xxxiii), wherein the compound of formula I and the one or more other antimalarial agent are administered simultaneously, concurrently, separately or sequentially.
  • xxxv) A further embodiment of the invention relates to a pharmaceutical composition comprising the combination according to any one of embodiments i) to xxx) and a pharmaceutically acceptable carrier. Based on the dependencies of the different embodiments i) to xxix) as disclosed hereinabove, the following embodiments are thus possible and intended and herewith specifically disclosed in individualized form:
  • salts refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. 1986, 33, 201 -217.
  • the term "combination" means a fixed combination with defined amounts of the combination partners or it means a "kit of parts" in the sense that the combination partners as defined herein can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners, i.e., simultaneously, concurrently, separately or sequentially.
  • the parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
  • the total amounts and the ratio of the total amounts of the combination partners to be administered can be varied, e.g.
  • the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of formula I, which compounds are identical to the compounds of formula I except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopically labelled, especially 2 H (deuterium) labelled compounds of formula I and salts thereof are within the scope of the present invention.
  • the compounds of formula I are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula I are not isotopically labelled at all. Isotopically labelled compounds 1 of formula I may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
  • the combinations of the present invention can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such as especially oral) or parenteral (including topical application or inhalation) administration, and are suitable for the treatment and/or prevention of the diseases mentioned herein, such as especially malaria.
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21 st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula I or their pharmaceutically acceptable salts or the other antimalarial agents, or a compound of formula I in combination with one or more other antimalarial agent according to the invention (fixed combinations), into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • antimalarial agents which according to the present invention can be used in combination with the compounds of formula I, are either commercially available or can be prepared as described in the literature. Alternatively, they can be prepared according to processes analogous to those known in the literature. These other antimalarial agents can be used either in free form or in the form of a pharmaceutically acceptable salt. Also, where appropriate, a prodrug, or - if present - an active metabolite of such other antimalarial agent can be used as combination partners according to the present invention.
  • In vitro antimalarial activity Plasmodium falciparum in vitro assay
  • the plates are incubated for a further 24 h under the same conditions then harvested with a Betaplate cell harvester (Wallac) and washed with distilled water.
  • the dried filters are inserted into a plastic foil with 10 mL of scintillation fluid, and counted in a Betaplate liquid scintillation counter.
  • IC 50 values are calculated from sigmoidal inhibition curves using Microsoft Excel.
  • In vivo antimalarial activity of the combinations of the present invention can be assessed for groups of three female NMRI mice (20-22 g) intravenously infected on day 0 with P. berghei strain GFP-ANKA (0.2 mL heparinized saline suspension containing 2 x 10 7 parasitized erythrocytes). In control mice, parasitemia typically rises to approximately 40% by day 3 after infection.
  • the compounds of the combination are formulated in Tween 80/ethanol (7%/3%) usually at concentrations of 10 mg/mL.
  • the compounds of the combination are administered in a volume of 10 mL/kg orally as single doses (1x100 mg/kg, 24 h after infection).

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison comprenant un composé de formule I et un ou plusieurs autres agents antipaludéens, destinée à être utilisée en particulier comme médicament dans le traitement ou la prévention d'infections paludéennes ou dans le traitement ou la prévention d'autres maladies protozoaires telles que la maladie du sommeil, la maladie de Chagas, l'amibiase, la lambliase, la trichomonase, la toxoplasmose, et la leishmaniose.
PCT/IB2012/053984 2011-08-04 2012-08-03 Combinaison d'agents antipaludéens WO2013018069A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB2011/053480 2011-08-04
IB2011053480 2011-08-04

Publications (1)

Publication Number Publication Date
WO2013018069A1 true WO2013018069A1 (fr) 2013-02-07

Family

ID=46881110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/053984 WO2013018069A1 (fr) 2011-08-04 2012-08-03 Combinaison d'agents antipaludéens

Country Status (1)

Country Link
WO (1) WO2013018069A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160024050A1 (en) * 2013-03-15 2016-01-28 Actelion Pharmaceuticals Ltd Novel acrylamide derivatives as antimalarial agents
CN107837289A (zh) * 2017-11-17 2018-03-27 中国农业科学院兰州畜牧与兽药研究所 一种用于治疗奶牛乳房炎症与痈肿的药物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083413A1 (fr) 2010-01-05 2011-07-14 Actelion Pharmaceuticals Ltd Pipérazines en tant qu'agents antipaludiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083413A1 (fr) 2010-01-05 2011-07-14 Actelion Pharmaceuticals Ltd Pipérazines en tant qu'agents antipaludiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Remington, The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing"
"Salt selection for basic drugs", INT. J. PHARM., vol. 33, 1986, pages 201 - 217
J. CHADWICK ET AL., CHEMMEDCHEM, 2011
J. WIESNER ET AL.: "Angewandte Chemie", vol. 115, 2003, pages: 5432 - 5451

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160024050A1 (en) * 2013-03-15 2016-01-28 Actelion Pharmaceuticals Ltd Novel acrylamide derivatives as antimalarial agents
US9637473B2 (en) * 2013-03-15 2017-05-02 Actelion Pharmaceuticals Ltd. Acrylamide derivatives as antimalarial agents
CN107837289A (zh) * 2017-11-17 2018-03-27 中国农业科学院兰州畜牧与兽药研究所 一种用于治疗奶牛乳房炎症与痈肿的药物及其制备方法
CN107837289B (zh) * 2017-11-17 2021-01-26 中国农业科学院兰州畜牧与兽药研究所 一种用于治疗奶牛乳房炎症与痈肿的药物及其制备方法

Similar Documents

Publication Publication Date Title
Mushtaque Reemergence of chloroquine (CQ) analogs as multi-targeting antimalarial agents: a review
Tekwani et al. 8-Aminoquinolines: future role as antiprotozoal drugs
JP5393679B2 (ja) アレナウイルス感染症を治療するための抗ウイルス薬
JP2004519469A5 (fr)
RU2008133654A (ru) Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
US4260615A (en) Antimalarial compositions
JP2887397B2 (ja) ニューモシスティス・カリニ肺炎などの疾病の治療法および予防法そしてこれらの方法に用いる化合物および処方物
WO2013018069A1 (fr) Combinaison d'agents antipaludéens
EP2521715B1 (fr) Pipérazines en tant qu'agents antipaludiques
JP5469095B2 (ja) 急性マラリアを治療するためのビス−チアゾリウム塩またはこれらの前駆体およびアルテミシニンまたはこれらの誘導体の組み合わせ
US20230165875A1 (en) Methylthioninium compounds for use in the treatment of covid-19
US20230158040A1 (en) Methylthioninium compounds for use in the treatment of hypoxemia
KR20090088379A (ko) 파탄적 행동 장애의 치료방법
US20230165876A1 (en) Methylthioninium compounds for use in the treatment of covid-19
JP2011526292A5 (fr)
CN101327217A (zh) 茚地那韦和氯喹在制备复方抗疟疾药物中的应用
US20120316178A1 (en) Piperazines as antimalarial agents
JPH0873355A (ja) 抗マラリア薬耐性克服剤
CN111084774A (zh) 吡咯烷类化合物组合物在制备抗疟疾药物中的应用
JPH02258722A (ja) 白血球の再生を可能にする新規な医薬組成物と、医薬と、後天性免疫不全症候群の治療へのその応用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12761812

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12761812

Country of ref document: EP

Kind code of ref document: A1